These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32286678)

  • 1. Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.
    Huang Z; Jiang Y; Chen J; Zhou Y
    Cardiol J; 2020; 27(2):171-174. PubMed ID: 32286678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
    Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
    Sinha S; Sehgal A; Sehgal R
    Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
    Kurdi A; Abutheraa N; Akil L; Godman B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.
    Braga CL; Silva-Aguiar RP; Battaglini D; Peruchetti DB; Robba C; Pelosi P; Rocco PRM; Caruso-Neves C; Silva PL
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00623. PubMed ID: 32658389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease and the impact of COVID-19.
    Yoganathan A; Sajjad MS; Harky A
    J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
    [No Abstract]   [Full Text] [Related]  

  • 7. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19.
    Kow CS; Zaidi STR; Hasan SS
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):217-221. PubMed ID: 32281055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.
    Singh AK; Gupta R; Misra A
    Diabetes Metab Syndr; 2020; 14(4):283-287. PubMed ID: 32283499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
    Mancia G; Rea F; Ludergnani M; Apolone G; Corrao G
    N Engl J Med; 2020 Jun; 382(25):2431-2440. PubMed ID: 32356627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
    Pirola CJ; Sookoian S
    J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
    Jennings GL
    Med J Aust; 2020 Jun; 212(11):502-503.e1. PubMed ID: 32441063
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
    Vitiello A; Ferrara F
    Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection.
    Salah HM; Calcaterra G; Mehta JL
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):503-507. PubMed ID: 32748634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

  • 18. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
    Vázquez-Cornejo E
    Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 20. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.